Replimune Inc.

This study is for people with advanced melanoma that has continued to grow despite receiving two standard types of immunotherapy. It aims to see if a new treatment—a modified virus injected directly into tumors, combined with the drug nivolumab—works better and helps people live …

This study is testing whether a new combination of an oncolytic virus therapy (RP2) and an immunotherapy drug (nivolumab) works better than the current standard immunotherapy combination for adults with metastatic uveal melanoma, a rare and aggressive cancer that starts in the ey…

This study is testing a new treatment called RP2, which is a modified virus designed to attack cancer cells and boost the immune system. It is for people with advanced liver cancer or bile duct cancer that has continued to grow despite standard treatment. The goal is to see if RP…

This study is testing an experimental therapy called RP1 for people who have had an organ or bone marrow transplant and now have advanced skin cancer. RP1 is a modified cold sore virus that is injected directly into tumors to try to destroy them and boost the body's immune respon…

This study is monitoring patients for five years after they received an experimental cancer immunotherapy from Replimune. The goal is to check for any delayed side effects or safety issues that might appear long after treatment. About 50 patients with cancers like melanoma or liv…